Myeloma Paper of the Day, June 11th, suggested by Robert Orlowski
Robert Orlowski shared on X:
“Myeloma Paper of the Day: Phase II trial of ixazomib/daratumumab/dexamethasone in relapsed/refractory myeloma finds ORR of 64.4%, VGPR rate of 30.5%, median PFS 16.8 months, and low rate of neuropathy (18.0% all grades, 1.6% grade ≥3).”
Source: Robert Orlowski/X
Authors: Sosana Delimpasi, Meletios Dimopoulos, Jan Straub, Argiris Symeonidis, Luděk Pour, Roman Hájek, Cyrille Touzeau, Viralkumar Bhanderi, Jesus Berdeja, Petr Pavlíček, Jeffrey Matous, Pawel Robak, Kaveri Suryanarayan, Alison Miller, Miguel Villarreal, Dasha Cherepanov, Jaydeep Srimani, Huilan Yao, Richard Labotka, and Robert Orlowski.
Other posts featuring Robert Orlowski on OncoDaily.
Robert Orlowski holds multiple positions at The University of Texas MD Anderson Cancer Center, including Chairman, Ad Interim Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics within the Division of Cancer Medicine.
Additionally, he chairs the SWOG Barlogie/Salmon Myeloma Committee, which is part of the National Clinical Trials Network, dedicated to advancing new therapies and understanding the biology of myeloma.
